Home> Products> short acting insulin secretion

{ "products": [ { "_id": "66616410ccd5ce1a107590a0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 1.0 ", "description": "RAPIGLINIDE VOG 1.0 \nRepaglinide (1mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 1.0\nRAPIGLINIDE VOG 1.0 is a combination medication that includes Repaglinide 1mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 1.0 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 1.0\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 1.0 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 1.0 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 1.0\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 1.0 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 1.0 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-1-0-134237", "price": 189.0, "discountamount": 56.7, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1415, "imageuri": "https://productimages.withfloats.com/actual/666164117b1fc3f9dd4c947c.png", "tileimageuri": "https://productimages.withfloats.com/tile/666164117b1fc3f9dd4c947c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:24:00.417Z", "updatedon": "2024-06-29T10:15:40.38Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/rapiglinide-vog-1-0-/1415", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 1.0 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 1.0", "Repaglinide (1mg)", "Voglibose (0.3mg)", "Repaglinide 1 mg uses", "Repaglinide 1 mg price", "Repaglinide mechanism of action", "" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "66616318d91d281c30c74f57", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "RAPIGLINIDE VOG 0.5 ", "description": "RAPIGLINIDE VOG 0.5 \nRepaglinide (0.5mg), Voglibose (0.3mg)\nIntroduction to RAPIGLINIDE VOG 0.5\nRAPIGLINIDE VOG 0.5 is a combination medication that includes Repaglinide 0.5mg and Voglibose 0.3mg. This medication is primarily used for the management of type 2 diabetes mellitus. By combining the complementary mechanisms of Repaglinide and Voglibose, RAPIGLINIDE VOG 0.5 offers comprehensive glycemic control, helping patients manage their blood sugar levels effectively.\n\nWhat are Repaglinide and Voglibose?\nOverview of Repaglinide\nRepaglinide is a meglitinide analog that helps control blood sugar levels by stimulating the pancreas to produce more insulin. It works by closing ATP-dependent potassium channels in the pancreatic beta-cell membrane, which leads to the opening of calcium channels and insulin release.\n\nOverview of Voglibose\nVoglibose is an alpha-glucosidase inhibitor that helps control blood sugar levels by slowing the digestion and absorption of carbohydrates in the small intestine. This leads to a slower and lower rise in blood glucose levels after meals.\n\nBenefits of RAPIGLINIDE VOG 0.5\nEffective Blood Sugar Management\nPostprandial Glucose Control: Repaglinide helps reduce blood sugar spikes after meals by stimulating rapid and short-acting insulin secretion. Voglibose complements this by slowing the absorption of carbohydrates, leading to a more gradual increase in blood glucose levels.\nComprehensive Glycemic Control: The combination of these two medications provides a dual mechanism of action that targets both insulin secretion and carbohydrate absorption, offering comprehensive blood sugar management.\nSupport for Diabetes Management\nDiet and Exercise Adjunct: RAPIGLINIDE VOG 0.5 is an excellent adjunct to diet and exercise, helping patients achieve better blood sugar control when lifestyle modifications alone are insufficient.\nReduced Risk of Complications: By maintaining more stable blood sugar levels, RAPIGLINIDE VOG 0.5 can help reduce the risk of long-term complications associated with diabetes, such as cardiovascular disease, neuropathy, and retinopathy.\nHow to Use RAPIGLINIDE VOG 0.5\nDosage and Administration\nRecommended Dosage: The typical dosage of RAPIGLINIDE VOG 0.5 is one tablet taken before each main meal. Your healthcare provider may adjust the dosage based on your individual response and blood sugar levels.\nAdministration: Take the tablet before each meal to enhance its effectiveness in controlling postprandial blood sugar spikes. Swallow the tablet whole with a full glass of water.\nGuidelines for Optimal Use\nConsistent Use: For best results, take RAPIGLINIDE VOG 0.5 regularly as prescribed by your healthcare provider.\nMonitor Blood Sugar Levels: Regularly check your blood sugar levels to ensure the medication is effectively controlling your diabetes. Adjustments to your treatment plan may be necessary based on these readings.\nFor further information: \nEMAIL: info@sterispharma.com / contact@sterispharma.com \n CALL/WHATSAPP: 7877551268, 7849827488 \n Order Now\nhttps://www.sterisonline.com/product/rapiglinide-vog-0-5-134238", "price": 145.0, "discountamount": 43.5, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 7, "_keywords": [ "Diet", "rapid", "Order", "EMAIL", "meals", "water", "slower", "action", "Support", "opening", "patients", "pancreas", "readings", "Benefits", "Overview", "Voglibose", "digestion", "main meal", "one tablet", "neuropathy", "full glass", "lower rise", "Guidelines", "information", "Adjustments", "Optimal Use", "Repaglinide", "retinopathy", "sterisonline", "sterispharma", "best results", "Introduction", "Reduced Risk", "CALL/WHATSAPP", "carbohydrates", "effectiveness", "typical dosage", "Consistent Use", "dual mechanism", "treatment plan", "Administration", "insulin release", "RAPIGLINIDE VOG", "small intestine", "two medications", "gradual increase", "calcium channels", "Exercise Adjunct", "excellent adjunct", "Recommended Dosage", "meglitinide analog", "Diabetes Management", "individual response", "healthcare provider", "blood sugar control", "blood glucose levels", "combination medication", "cardiovascular disease", "long-term complications", "lifestyle modifications", "carbohydrate absorption", "complementary mechanisms", "type 2 diabetes mellitus", "stable blood sugar levels", "alpha-glucosidase inhibitor", "Postprandial Glucose Control", "pancreatic beta-cell membrane", "short-acting insulin secretion", "comprehensive glycemic control", "postprandial blood sugar spikes", "ATP-dependent potassium channels", "Effective Blood Sugar Management", "comprehensive blood sugar management" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 1413, "imageuri": "https://productimages.withfloats.com/actual/6661631cc40ee9be019a5fd2.png", "tileimageuri": "https://productimages.withfloats.com/tile/6661631cc40ee9be019a5fd2.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2024-06-06T07:19:52.782Z", "updatedon": "2024-06-29T10:18:42.752Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/rapiglinide-vog-0-5-/1413", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE VOG 0.5 ", "category": "DIABETIC RANGE", "tags": [ "RAPIGLINIDE VOG 0.5", "Repaglinide (0.5mg),", "Voglibose (0.3mg)", "voglibose 0.3mg price in india", "voglibose 0.3mg uses", "voglibose 0.3mg dosage" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": "", "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "68b0256b813270ffac595cb0", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "trelagliptin 100 mg", "description": "TRELAQWK 100 is an advanced oral antidiabetic medication containing Trelagliptin 100 mg, specifically designed for adults with type 2 diabetes mellitus (T2DM). Belonging to the class of Dipeptidyl Peptidase-4 (DPP-4) inhibitors, this formulation helps improve blood glucose control when used along with a proper diet and regular exercise.\nWith its once-weekly dosage regimen, TRELAQWK 100 offers a convenient treatment option, enhancing patient compliance and simplifying long-term diabetes management.\nKey Ingredient\nTrelagliptin 100 mg\nA long-acting DPP-4 inhibitor that regulates blood glucose levels by enhancing incretin hormones. These incretins stimulate insulin secretion and suppress glucagon release, helping to achieve better glycemic control.\nKey Benefits of TRELAQWK 100\nWeekly dosing ensures greater convenience and adherence\nReduces both fasting and postprandial blood sugar levels\nSupports natural blood sugar regulation without weight gain\nLow risk of hypoglycemia, especially when used as monotherapy or with non-insulin therapies\nCan be prescribed as monotherapy or in combination with other antidiabetic agents like metformin or sulfonylureas\nHow TRELAQWK 100 Works\nTRELAQWK 100 functions by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).\nThese incretin hormones:\nStimulate insulin secretion in response to meals\nReduce glucagon release, lowering blood sugar levels\nThanks to its extended half-life, trelagliptin allows for once-weekly dosing, unlike other DPP-4 inhibitors that require daily administration.\nDirections for Use\nDosage: Take one tablet of TRELAQWK 100 once weekly, or as directed by your physician\nAdministration: May be taken with or without food, ideally on the same day each week\nMissed dose: Do not double the dose; consult your healthcare provider for guidance\nPossible Side Effects\nTRELAQWK 100 is usually well-tolerated, but some individuals may experience:\nMild headache\nNasopharyngitis (common cold-like symptoms)\nConstipation\nUpper respiratory tract infections\nRare skin allergies (rash, itching)\n👉 If you experience persistent abdominal pain, severe rashes, or symptoms suggestive of pancreatitis, stop the medication and seek medical care immediately.", "price": 517.0, "discountamount": 156.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2166, "imageuri": "https://productimages.withfloats.com/actual/68b0256ebb42c3d551ad314c.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b0256ebb42c3d551ad314c.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:46:19.602Z", "updatedon": "2025-12-09T06:14:45.346Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelagliptin-100-mg/2166", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRELAQWK 100", "category": "DIABETIC RANGE", "tags": [ "trelagliptin 100 mg", "diabetes mellitus (T2DM)", "blood sugar levels" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "68b02393f5434d48fca8b8ca", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "trelagliptin 50 mg", "description": "TRELAQWK 50 is a modern oral antidiabetic tablet containing Trelagliptin 50 mg, specially developed for adults with type 2 diabetes mellitus. This once-weekly medication helps regulate blood sugar effectively, offering both convenience and strong clinical outcomes. With its advanced formulation, TRELAQWK 50 supports better glycemic control, making it easier for patients to lead a balanced and healthier lifestyle.\nManufactured under strict quality standards, TRELAQWK 50 ensures patient compliance, long-term safety, and efficacy in diabetes management.\nKey Ingredient\nTrelagliptin (50 mg):\nA unique, long-acting DPP-4 (dipeptidyl peptidase-4) inhibitor that allows weekly dosing, ensuring higher treatment adherence while maintaining effective control over blood glucose levels.\nKey Benefits of TRELAQWK 50\nProvides consistent blood sugar management with just one tablet per week\nEnhances insulin secretion while lowering glucagon levels in a glucose-dependent manner\nHelps reduce both fasting and postprandial blood glucose\nConvenient choice for patients with busy schedules who struggle with daily tablets\nLow risk of hypoglycemia when used as monotherapy\nSupports long-term improvement in HbA1c levels\nMechanism of Action – How TRELAQWK 50 Works\nTRELAQWK 50 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These incretins are vital for maintaining blood sugar balance. By prolonging incretin activity, trelagliptin:\nStimulates insulin secretion from the pancreas\nReduces glucagon release from alpha cells\nHelps lower blood sugar, particularly after meals\nThis mechanism provides both effective glycemic control and improved patient compliance.\nDirections for Use\nTake one tablet of TRELAQWK 50 once a week, on the same day each week\nCan be taken with or without food\nSwallow whole with a glass of water\nFollow your doctor’s advice for dosage adjustment\nDo not double the dose if missed; consult your healthcare provider\nPossible Side Effects\nTRELAQWK 50 is usually well-tolerated. However, some patients may experience:\nMild headache\nNasopharyngitis (cold-like symptoms)\nDiarrhea\nStomach discomfort or indigestion\nRare allergic reactions (rash, itching)\nIf any unusual or persistent side effects occur, seek medical advice promptly.", "price": 352.0, "discountamount": 106.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2165, "imageuri": "https://productimages.withfloats.com/actual/68b023971624ba892ffd8c69.png", "tileimageuri": "https://productimages.withfloats.com/tile/68b023971624ba892ffd8c69.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-08-28T09:38:27.036Z", "updatedon": "2025-12-09T06:14:54.989Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelagliptin-50-mg/2165", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "TRELAQWK 50", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin 50 mg", "2 diabetes mellitus", "blood sugar", "TRELAQWK 50" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6842b8014256f7114dfbd884", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "TRELAQWK 100", "description": "Trelagliptin 100mg in TRELAQWK 100 is an innovative once-weekly oral medication formulated with Trelagliptin 100mg, specifically designed to support adults in managing type 2 diabetes mellitus (T2DM). As a member of the Dipeptidyl Peptidase-4 (DPP-4) inhibitor class, it provides a simplified and effective approach to improving glycemic control when combined with a healthy diet and regular exercise. Its weekly dosing schedule enhances treatment adherence, offering a more sustainable option for long-term diabetes care.\n\nActive Ingredient:\nTrelagliptin 100mg\nA potent, long-acting DPP-4 inhibitor that helps maintain stable blood glucose levels by preserving incretin activity. Incretins are natural hormones that promote insulin release and suppress glucagon, playing a vital role in blood sugar regulation.\n\nCore Benefits:\nConvenient once-weekly dosing enhances patient compliance\n\nEffectively lowers both fasting and postprandial (after-meal) blood sugar\n\nPromotes natural insulin production without contributing to weight gain\n\nCarries a low risk of hypoglycemia, especially when not used with insulin\n\nCan be used alone or in combination with other antidiabetic medications like metformin or sulfonylureas\n\nMechanism of Action:\nTRELAQWK 100 works by blocking the DPP-4 enzyme, which normally degrades incretin hormones such as GLP-1 and GIP. These hormones play a crucial role in regulating blood sugar after meals. By prolonging their activity, Trelagliptin enhances insulin secretion and reduces glucagon levels, resulting in improved glycemic control. Its extended half-life allows for once-a-week administration, setting it apart from daily DPP-4 inhibitors.\n\nDosage & Administration:\nRecommended Dose: One tablet per week, or as advised by your doctor\n\nHow to Take: With or without food, preferably on the same day each week\n\nIf a dose is missed, do not double the next dose; seek guidance from your healthcare provider\n\nPossible Side Effects:\nTRELAQWK 100 is generally safe and well-tolerated. Some individuals may experience:\n\nHeadache\n\nNasopharyngitis (mild cold symptoms)\n\nConstipation\n\nUpper respiratory tract infections\n\nRare allergic reactions such as rashes or skin irritation\n\nSeek immediate medical advice if you experience unusual symptoms such as severe abdominal pain, persistent skin reactions, or signs of pancreatitis.", "price": 517.0, "discountamount": 155.81, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medical advice", "generally safe", "healthcare provider", "food preferably", "extended halflife", "crucial role", "dpp4 enzyme", "sulfonylureas mechanism", "antidiabetic medications", "low risk", "vital role", "sustainable option", "regular exercise", "healthy diet", "effective approach", "support adults", "trelaqwk 100trelaqwk 100", "hormones play", "natural hormones", "dose seek guidance", "promote insulin release", "degrades incretin hormones", "experience unusual symptoms", "skin irritation seek", "onceaweek administration setting", "improved glycemic control", "regulating blood sugar", "weight gain carries", "suppress glucagon playing", "improving glycemic control" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2132, "imageuri": "https://productimages.withfloats.com/actual/6842b80c8a53ae8db15a02ac.png", "tileimageuri": "https://productimages.withfloats.com/tile/6842b80c8a53ae8db15a02ac.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-06-06T09:42:25.371Z", "updatedon": "2025-12-02T08:08:22.899Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/trelaqwk-100/2132", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Trelagliptin 100mg", "category": "DIABETIC RANGE", "tags": [ "Trelagliptin side effects", "Trelagliptin brand name", "Trelagliptin brands in India", "Trelagliptin uses", "Trelagliptin 100mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "6825c6cc966e2a18bb4b35a6", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "GLIDAPA PIO", "description": "GLIDAPA PIO is a combination oral medication specially formulated to help manage type 2 diabetes mellitus. It combines two powerful antidiabetic agents, dapagliflozin and pioglitazone, to effectively control blood sugar levels. This medication is prescribed to patients when diet and exercise alone do not provide adequate glycemic control. By addressing blood glucose regulation through different mechanisms, GLIDAPA PIO helps reduce the risk of diabetes-related complications and supports overall metabolic health.\n\nKey Ingredients\nDapagliflozin (10mg): A sodium-glucose co-transporter 2 (SGLT2) inhibitor that helps lower blood sugar by increasing the excretion of glucose through urine.\n\nPioglitazone (15mg): A thiazolidinedione that improves insulin sensitivity by acting on fat, muscle, and liver cells, facilitating better glucose uptake and utilization.\n\nKey Benefits\nHelps maintain stable blood glucose levels in adults with type 2 diabetes.\n\nCombines two complementary mechanisms to enhance blood sugar control.\n\nSupports weight management due to dapagliflozin’s glucose excretion effect.\n\nMay improve insulin sensitivity and reduce insulin resistance.\n\nReduces the risk of diabetes-related complications such as cardiovascular problems when combined with lifestyle changes.\n\nConvenient once-daily tablet formulation.\n\nHow Does It Work?\nDapagliflozin blocks SGLT2 proteins in the kidneys, preventing glucose reabsorption and promoting its elimination through urine, which lowers blood glucose. Pioglitazone acts on insulin-responsive tissues, enhancing the body’s sensitivity to insulin. This dual action helps reduce both insulin resistance and excess blood glucose, providing better overall glycemic control. By targeting different pathways, GLIDAPA PIO offers a synergistic effect to manage type 2 diabetes more effectively.\n\nDirections for Use\nTake GLIDAPA PIO exactly as prescribed by your healthcare provider.\n\nUsually taken once daily, with or without food, at the same time each day.\n\nDo not skip doses or stop the medication without consulting your doctor.\n\nMaintain a balanced diet and regular exercise as advised alongside the medication.\n\nInform your doctor about any other medications you are taking to avoid potential interactions.\n\nSide Effects\nSome patients may experience side effects while taking GLIDAPA PIO, including:\n\nUrinary tract infections or increased urination due to dapagliflozin.\n\nWeight gain or swelling caused by pioglitazone.\n\nRisk of low blood sugar (hypoglycemia) when combined with other antidiabetic drugs.\n\nPossible dizziness or fatigue.\n\nRarely, heart failure or bladder cancer risk (associated with pioglitazone).\n\nIf you notice symptoms like excessive thirst, sudden weight gain, swelling, shortness of breath, or any allergic reactions, seek medical advice immediately.", "price": 255.0, "discountamount": 77.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "medication inform", "pioglitazone risk", "regular exercise", "balanced diet", "doctor maintain", "glucose uptake", "notice symptoms", "antidiabetic drugs", "swelling caused", "advised alongside", "skip doses", "healthcare provider", "effectively directions", "synergistic effect", "glycemic control", "cardiovascular problems", "complementary mechanisms", "fat muscle", "diabetesrelated complications", "insulin resistance", "bodys sensitivity", "glidapa pio", "urine pioglitazone 15mg", "taking glidapa pio", "bladder cancer risk", "improve insulin sensitivity", "improves insulin sensitivity", "glidapa pioglidapa pio", "dapagliflozin weight gain", "increased urination due", "urinary tract infections", "experience side effects", "insulinresponsive tissues enhancing", "liver cells facilitating" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2114, "imageuri": "https://productimages.withfloats.com/actual/6825c6ce65488af627fb2e46.png", "tileimageuri": "https://productimages.withfloats.com/tile/6825c6ce65488af627fb2e46.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-05-15T10:49:48.361Z", "updatedon": "2025-12-08T07:45:25.909Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/glidapa-pio/2114", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "Dapagliflozin 10mg and pioglitazone 15mg tablets", "category": "DIABETIC RANGE", "tags": [ "Dapagliflozin, pioglitazone combination", "Dapagliflozin, pioglitazone combination", "Dapagliflozin Pioglitazone CDSCO" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "67c5887fcd301704c9b6528a", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Repaglinide 0.5mg", "description": "RAPIGLINIDE 0.5 contains Repaglinide 0.5 mg, a medication used in the treatment of Type 2 diabetes mellitus. It belongs to a class of drugs known as meglitinides, which help control blood sugar levels by stimulating insulin production from the pancreas. RAPIGLINIDE is commonly prescribed to individuals who are unable to maintain optimal blood glucose levels through diet and exercise alone. It can be used alone or in combination with other oral diabetes medications to help manage blood sugar levels effectively.\n\n \nKey Benefits:\n \n Effective Blood Sugar Control – Helps lower postprandial blood glucose levels, effectively managing blood sugar spikes after meals.\n Rapid Action – Starts working quickly, offering fast relief from elevated blood sugar levels.\n Flexible Dosing – Can be taken before meals, giving flexibility in meal planning and diabetes management.\n Helps Prevent Complications of Diabetes – By controlling blood sugar levels, it helps in reducing the risk of complications associated with diabetes, such as nerve damage, heart disease, and kidney issues.\n Used Alone or with Other Diabetes Medications – RAPIGLINIDE 0.5 can be combined with other oral diabetes drugs for better blood sugar management.\n\n \nHow Does It Work?\n \n\nRepaglinide 0.5 mg works by stimulating the beta cells in the pancreas to secrete insulin when blood sugar levels rise after meals. The medication acts quickly, allowing the body to use glucose more effectively and preventing high blood sugar spikes. Unlike other long-acting insulin medications, Repaglinide acts quickly but for a short duration, making it suitable for controlling blood sugar right after eating. It helps in maintaining optimal postprandial glucose levels, which is crucial for the management of Type 2 diabetes.\n\n \nDirections for Use:\n \n\nTake RAPIGLINIDE 0.5 exactly as prescribed by your doctor.\nThe typical dosage is 0.5 mg to 2 mg taken before meals, 2 to 3 times daily.\nSwallow the tablet whole with water.\nDo not take more than the prescribed dose, and never skip doses.\nIf you miss a dose, take it as soon as you remember before the next meal. If it's almost time for your next meal, skip the missed dose—do not double the dose.\n \nSide Effects:\n \n\nWhile RAPIGLINIDE 0.5 is generally well-tolerated, some people may experience:\n\nHypoglycemia (low blood sugar): Symptoms include dizziness, sweating, shaking, confusion, and headaches.\nNausea or diarrhea\nWeight gain (in some cases)\nHeadache or dizziness\nRash or itching (rare)\nAbdominal discomfort\nIf you experience any signs of severe hypoglycemia (such as confusion, blurred vision, or seizures), or severe allergic reactions (such as difficulty breathing, swelling of the face or throat), seek immediate medical attention.", "price": 217.0, "discountamount": 66.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": [ "2 mg", "05 mg", "rapiglinide 05", "meals 2", "pancreas rapiglinide", "repaglinide 05 mg", "meal skip", "prescribed dose", "meal planning", "commonly prescribed", "medical attention", "throat seek", "dizziness rash", "cases headache", "headaches nausea", "generally welltolerated", "missed dosedo", "skip doses", "typical dosage", "beta cells", "kidney issues", "repaglinide 05mgrapiglinide 05", "severe hypoglycemia", "secrete insulin", "oral diabetes drugs", "stimulating insulin production", "meals giving flexibility", "dose side effects", "blood sugar management", "oral diabetes medications", "severe allergic reactions", "difficulty breathing swelling", "confusion blurred vision", "diarrhea weight gain", "controlling blood sugar", "short duration making" ], "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2063, "imageuri": "https://productimages.withfloats.com/actual/67c588a2587befa5fb853a41.png", "tileimageuri": "https://productimages.withfloats.com/tile/67c588a2587befa5fb853a41.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-03-03T10:46:23.834Z", "updatedon": "2025-12-06T06:18:03.766Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/repaglinide-0-5mg/2063", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "RAPIGLINIDE 0.5", "category": "DIABETIC RANGE", "tags": [ "Repaglinide 0.5 Mg Tablet Uses in Hindi", "Repaglinide 0.5 mg tablet uses", "Repaglinide 0.5 mg brand name", "Repaglinide brand name", "Repaglinide side effects 0.5 mg" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.001, "isnotforsale": false }, { "_id": "693c0f0df827a9801a26dcd7", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Isosorbide mononitrate IP 60mg Tablets", "description": "CARDULES ISMN SR 60 delivers Isosorbide Mononitrate IP 60mg in a sustained-release tablet form, designed for long-term prevention of angina in patients with coronary artery disease. Produced by Steris Healthcare Pvt Ltd, this formulation ensures steady drug release over 12-24 hours, optimizing cardiovascular protection with once-daily dosing convenience. It supports heart health by enhancing blood flow without the peaks and troughs of immediate-release options.​\n\nProduct Overview\nCARDULES ISMN SR 60 contains Isosorbide Mononitrate IP 60mg per sustained-release tablet, a pure nitrate metabolite that bypasses first-pass liver metabolism for consistent bioavailability. The SR technology employs a polymer matrix to gradually liberate the active ingredient, maintaining therapeutic plasma levels throughout the day and minimizing tolerance development associated with frequent dosing. Available in strips of 10 tablets, it features a film-coated exterior for easy swallowing and gastro-resistant properties to protect against stomach acid degradation.​\n\nThis higher 60mg strength suits patients requiring intensified prophylaxis after initial titration from lower doses like 30mg or 40mg. It integrates seamlessly into comprehensive cardiac regimens alongside beta-blockers, statins, or aspirin, under cardiologist supervision. Quality manufacturing adheres to IP standards, ensuring purity above 99% with low impurity profiles for safety in chronic use.​\n\nKey Uses\nCARDULES ISMN SR 60 primarily prevents chronic stable angina pectoris by dilating coronary arteries and reducing myocardial oxygen demand during exertion. Patients experience fewer episodes of chest tightness, pressure, or discomfort triggered by physical activity, stress, or cold exposure.​\n\nIt manages coronary artery disease (CAD) by improving collateral circulation and easing ischemia in narrowed vessels. Often prescribed post-angioplasty or alongside lifestyle modifications, it stabilizes symptoms for enhanced daily functioning.​\n\nAdditionally, it supports adjunctive therapy in congestive heart failure or post-myocardial infarction recovery, where vasodilation unloads the heart. Not for acute attacks—use sublingual nitroglycerin instead—but vital for long-term risk reduction.​\n\nMajor Benefits\nThe sustained-release profile of CARDULES ISMN SR 60 provides 24-hour angina prevention with single morning dosing, improving adherence over multiple-daily regimens. This steady vasodilation lowers preload via venous pooling and afterload via arterial relaxation, cutting oxygen consumption by up to 20-30% during stress.​\n\nPatients report increased exercise tolerance, with treadmill tests showing delayed onset of ST-segment depression. Enhanced myocardial perfusion boosts energy levels, enabling return to work, hobbies, or family activities without fear of sudden symptoms.​\n\nCompared to shorter-acting nitrates, tolerance buildup is slower due to a nitrate-free interval built into once-daily use. Cost-effective at higher strengths, it reduces overall healthcare visits and hospitalization risks from unstable angina.​\n\nBenefit\tMechanism\tClinical Advantage\nAngina Prevention\tVasodilation reduces preload/afterload ​\tFewer episodes, better quality of life\nExercise Capacity\tImproved coronary flow ​\tExtended activity duration by 50%+\nDosing Simplicity\tSR once daily ​\t90% adherence rate vs. multiple doses\nHeart Protection\tLowers ischemia risk. ​\tReduced MI recurrence\nPotential Side Effects\nCommon effects include headache (orthostatic or throbbing), especially in the first week, resolving with hydration and dose acclimation—acetaminophen helps manage it. Dizziness, lightheadedness, or postural hypotension may occur; rise slowly from sitting.​\n\nGastrointestinal upset like nausea or flushing affects 5-10% initially. Avoid alcohol or PDE5 inhibitors (e.g., sildenafil) to prevent severe hypotension.​\n\nRarely, reflex tachycardia, rash, or methemoglobinemia arises; monitor liver enzymes in prolonged use. Contraindicated in severe anemia, glaucoma, or recent PDE5 intake—discontinue if allergic reactions appear.​\n\nDosage Guidelines\nInitiate at 30-40mg daily, titrating to 60mg once in the morning on an empty stomach for optimal absorption. Swallow whole; do not crush. A 10-12 hour nitrate-free window (nighttime) prevents tolerance.​\n\nAdjust for renal/hepatic impairment; max 120mg/day. Store below 25°C. Regular ECG and BP checks ensure efficacy.​\nConclusion\nCARDULES ISMN SR 60 stands as a cornerstone in angina prophylaxis, empowering CAD patients with reliable, sustained vascular relief from Steris Healthcare. Consistent use alongside diet, exercise, and smoking cessation maximizes outcomes, but cardiologist oversight remains essential for safety", "price": 155.0, "discountamount": 47.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2244, "imageuri": "https://productimages.withfloats.com/actual/693c0f14d878634fd7a965ca.png", "tileimageuri": "https://productimages.withfloats.com/tile/693c0f14d878634fd7a965ca.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-12T12:48:13.762Z", "updatedon": "2025-12-16T05:41:10.59Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/isosorbide-mononitrate-ip-60mg-tablets/2244", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CARDULES ISMN SR 60", "category": "cardiology", "tags": [ "Isosorbide mononitrate IP 60mg Tablets", "coronary artery disease", "supports heart health by enhancing blood flow", "gastro-resistant properties to protect against stomach acid", "Contraindicated in severe anemia, glaucoma, or recent PDE5" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false }, { "_id": "693c0c9c0c30ac5c9f8203b4", "fptag": "STERISHEALTHCARE", "merchantname": null, "customwidgets": null, "externalsourceid": null, "name": "Isosorbide Mononitrate IP 30mg Tablets", "description": "CARDULES ISMN SR 30 tablets provide sustained-release Isosorbide Mononitrate IP 30mg, a nitrate medication designed for long-term management of angina in patients with coronary artery disease. This formulation from Steris Healthcare Pvt Ltd ensures steady vasodilation to improve heart blood flow and reduce chest pain episodes. It supports daily activities by minimizing oxygen demand on the heart muscle.​\nProduct Overview\nCARDULES ISMN SR 30 contains Isosorbide Mononitrate IP 30mg in a sustained-release matrix, allowing once-daily dosing for consistent therapeutic levels over 12-24 hours. The tablet's extended-release technology prevents peak-trough fluctuations common in immediate-release forms, promoting better patient compliance. Each film-coated tablet delivers precise bioavailability, with the active metabolite nitric oxide activating guanylate cyclase to boost cyclic GMP, relaxing vascular smooth muscle primarily in veins.​\n\nThis mechanism reduces preload (venous return to the heart) and afterload (arterial resistance), easing cardiac workload without significantly affecting heart rate. Unlike short-acting nitrates for acute relief, CARDULES ISMN SR 30 targets prophylaxis in chronic stable angina, often prescribed alongside beta-blockers or calcium channel blockers. Available in strips of 10 tablets, it undergoes rigorous quality testing at Steris facilities to meet IP standards, ensuring purity and stability.​\n\nKey Uses\nCARDULES ISMN SR 30 primarily prevents angina pectoris in coronary artery disease, where narrowed vessels limit oxygen supply during exertion. Patients experience fewer chest pain attacks during walking, climbing stairs, or stress.​\n\nIt manages chronic stable angina by enhancing myocardial perfusion, suitable for long-term therapy in adults over 18. Healthcare providers may use it adjunctively for coronary spasm or post-myocardial infarction prophylaxis to stabilize symptoms.​\n\nIn select cases, it aids heart failure management by offloading the heart, though not as monotherapy. Always initiate under cardiology supervision with dose titration to tolerance.​\n\nMajor Benefits\nThe sustained-release profile offers 24-hour protection with single morning dosing, improving adherence and lifestyle quality for active patients. It boosts exercise tolerance by 20-30% in trials, allowing longer physical efforts without angina onset.​\n\nBy dilating vessels, it decreases ischemia risk, potentially lowering hospitalization rates for acute episodes. Compared to placebo, users report halved attack frequency within weeks, enhancing daily productivity and emotional well-being.​\n\nBenefit\tMechanism\tPatient Outcome\nAngina Prevention\tVasodilation reduces preload/afterload ​\tFewer attacks, better exertion capacity\nSteady Relief\tSR formulation maintains levels ​\tOnce-daily convenience, no fluctuations\nHeart Protection\tImproves O2 delivery ​\tReduced ischemia, enhanced QoL\nCompliance Boost\tSimple regimen ​\tHigher adherence vs multiple doses\nAdditional perks include minimal impact on blood pressure in normotensives and compatibility with anti-anginals, making it versatile in combo therapy.\n\nPotential Side Effects\nCommon effects include headache (dose-related, often transient in first week), dizziness, or flushing due to vasodilation—hydrate and rise slowly to manage. Gastrointestinal upset like nausea occurs in 5-10% initially.​\n\nOrthostatic hypotension risks fainting, especially early; avoid alcohol or other vasodilators. Rare serious issues encompass severe hypotension, tachycardia, or methemoglobinemia with overdose—monitor blood pressure regularly.​\n\nAllergic reactions (rash, itching) or vision changes warrant discontinuation. Contraindicated in hypotension, glaucoma, or recent PDE5 inhibitor use; caution in anemia or hypothyroidism.​\n\nDosage Guidelines\nStart with 30mg once daily upon waking, swallowed whole without crushing. Titrate to 60mg if tolerated after 3-7 days, max 120mg/day. Take on empty stomach for optimal absorption; avoid late dosing to prevent nocturnal headaches.​\n\nAdjust for elderly or renal/hepatic impairment. Tolerance may develop—nitrate-free interval (evening) helps sustain efficacy. Store below 30°C.​\nConclusion\nCARDULES ISMN SR 30 empowers angina patients with reliable, once-daily prevention, restoring confidence in routine activities under Steris Healthcare's quality assurance. Its targeted vasodilation balances efficacy and tolerability for sustained heart health", "price": 65.0, "discountamount": 19.0, "currencycode": "INR", "priority": 1000000, "isfreeshipmentavailable": false, "shipmentduration": 1, "_keywords": null, "isarchived": false, "isavailable": true, "applicationid": null, "productindex": 2243, "imageuri": "https://productimages.withfloats.com/actual/693c0ca6391a3fa44b0608d8.png", "tileimageuri": "https://productimages.withfloats.com/tile/693c0ca6391a3fa44b0608d8.png", "images": null, "totalqueries": 0, "gpid": null, "groupproductid": null, "createdon": "2025-12-12T12:37:48.92Z", "updatedon": "2025-12-12T12:37:48.92Z", "buyonlinelink": null, "producturl": "http://WWW.STERISINDIA.COM/products/isosorbide-mononitrate-ip-30mg-tablets/2243", "availableunits": -1.0, "iscodavailable": false, "isprepaidonlineavailable": false, "maxcodorders": 0, "maxprepaidonlineorders": 0, "uniquepaymenturl": null, "brandname": "CARDULES ISMN SR 30", "category": "", "tags": [ "Isosorbide Mononitrate IP 30mg Tablets", "coronary artery disease", "heart blood flow and reduce chest pain episodes", "oxygen demand on the heart muscle", "relaxing vascular smooth muscle primarily in veins" ], "variants": false, "keyspecification": null, "otherspecifications": null, "pickupaddressreferenceid": null, "paymenttype": "UniquePaymentUrl", "producttype": "products", "hsncode": null, "gstslab": 0.0, "isnotforsale": false } ], "hasmoreitems": false, "isapirequest": false, "totalresults": 27, "query": null, "floatingpoint": null }